Popular stacks

Goal. Sustained weight loss + metabolic improvement (HbA1c, lipid panel, blood pressure).

Stack. Tirzepatide or Semaglutide. Single-agent — they don't combine. • Tirzepatide: titrate 2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg once weekly, escalating every 4 weeks. • Semaglutide: titrate 0.25 → 0.5 → 1 → 1.7 → 2.4 mg once weekly.

Cycle. Long-term — months to years. The phase-3 trials ran 68–72 weeks; weight regain is common after discontinuation.

Evidence. Tier 1 (RCT-supported, FDA-approved).

Stack rationale. Best-in-class evidence; ~14–22% mean body weight reduction in placebo-controlled trials. SELECT trial added cardiovascular benefit for semaglutide.

Goal. Tendon, ligament, gut, and muscle healing post-injury or surgery.

Stack. • BPC-157: 200–500 mcg subcutaneous, 1–2× daily. • TB-500: 2–5 mg subcutaneous, twice weekly during a 4–6 week loading phase, then 1× weekly maintenance.

Cycle. Most community protocols run 4–6 weeks on, then off. The cap reflects unknown long-term human safety, not a known toxicity threshold.

Evidence. Tier 3. Animal data for both compounds is large and consistent; no published human RCTs of either.

Stack rationale. BPC-157 is positioned as the more local-acting compound; TB-500 the more systemic. The combination is pure community knowledge — there's no human evidence the pair works better than either alone.

Athlete warning. TB-500 (Thymosin Beta-4) is on the WADA prohibited list (S2). Banned for competitive athletes.

Goal. Amplify the body's natural overnight GH pulse for body composition, recovery, and (anecdotally) sleep depth.

Stack. Both drawn into the same syringe and injected together: • CJC-1295 (no-DAC, Mod GRF 1-29): 100–300 mcg. • Ipamorelin: 100–300 mcg. • 1–3× daily, subcutaneous, fasted (1–2 h after a meal). Bedtime is the dominant timing.

Cycle. 8–12 weeks on, 4–8 weeks off (community protocol; no clinical guidance).

Evidence. Tier 3. Mechanistically clean — CJC-1295 stimulates the pituitary, Ipamorelin amplifies via the ghrelin receptor. But there are no longevity / body-composition outcome RCTs.

Stack rationale. GHRH + GHRP synergy is well-documented in mechanistic studies; outcomes data is community-reported.

With-DAC alternative. CJC-1295 with-DAC is a separate protocol — once weekly, sustained elevation rather than pulsatile. Community is split on whether unphysiologic steady-state signaling is desirable.

Goal. Reduce visceral adipose tissue (the abdominal-organ-surrounding fat that drives metabolic risk), independent of total body weight.

Stack. Tesamorelin 2 mg subcutaneous daily, bedtime, fasted.

Cycle. FDA-approved indication (HIV lipodystrophy) studies use long-term continuous dosing. Off-label community protocols typically run 12–26 weeks; the question of when to stop has no clinical guidance.

Evidence. Tier 1 for HIV-associated lipodystrophy (the approved indication). Tier 2–3 off-label for non-HIV visceral fat reduction.

Stack rationale. Tesamorelin has the strongest evidence base of any GHRH analog because the FDA approved it. Community uses it for the same mechanism in a different population.

Goal. Skin rejuvenation, collagen synthesis, wound healing, hair density.

Stack. GHK-Cu 0.1–2% topical formulation, twice daily on cleansed skin (AM and PM).

Cycle. Continuous — topical use is well-tolerated long-term in cosmetic and wound-care studies.

Evidence. Tier 2 for topical use — multiple human studies on collagen synthesis, wound healing, and cosmetic outcomes.

Important. Tier 3 for injectable / systemic GHK-Cu. The topical evidence does not transfer to a different route of administration; injectable claims are mechanistic speculation.

Stack rationale. Routine layering: under sunscreen AM, with retinol-free routine PM (some users find combined retinol + GHK-Cu irritating).

Honest gap. The community protocols circulating online include peptides we don't yet cover in the library. We don't list those stacks because each new peptide needs evidence-tier classification and cited primary sources before going live, and we won't fake it.

Categories you'll see elsewhere that we haven't shipped yet: • Cognitive / focus — Semax, Selank, Dihexa. • Hormone / libido — PT-141 (bremelanotide), Kisspeptin. • Mitochondrial / energy — MOTS-c, SS-31 (elamipretide), NAD+. • Muscle building — IGF-1 LR3, Follistatin-344, Sermorelin. • Fat-loss adjunct — AOD-9604, 5-Amino-1MQ, SLU-PP-332, Retatrutide (though Retatrutide is approaching FDA review). • Cycle longevity — Epitalon, KPV.

Roadmap. Phase 2 expands the library with 10–20 more peptides. Until then, treat content elsewhere about these compounds skeptically — most of it skips evidence tiers entirely.